The University of California, San Francisco today announced a collaboration with GE Healthcare, a unit of General Electric Company (NYSE: GE), to develop new technology for clinical use that tracks real-time changes in tissue metabolism with unprecedented sensitivity.
The collaboration will focus on developing new magnetic resonance (MR) imaging and spectroscopy techniques that are expected to enable earlier diagnosis and treatment of cancer and other diseases tailored to individual patients.
The pre-clinical and clinical studies will be carried out at the California Institute for Quantitative Biomedical Research, or QB3, headquartered at UCSF's Mission Bay campus.
"Although MR images are widely used in a clinical setting, the information they provide is often limited, resulting in diseases such as cancer being detected only late in their cycle -- when treatments are costly or ineffective," said Sarah Nelson, PhD
, UCSF professor of radiology and director of the Surbeck Laboratory of Advanced Imaging at QB3.
"Improved characterization of the disease is critical in efforts to influence the chances of survival and make more treatment options available. The high field MR scanners at QB3 will significantly improve sensitivity and specificity, allowing us to more effectively target therapy and provide non-invasive biomarkers of response to new therapies," she said.
Read more at Wallace Ravven, UCSF News Services